ストックスクリーナーアプリを入手
0.138
4.15%
0.0055
前日終値:
$0.1325
開ける：
$0.1325
24時間の取引高:
10,901
Relative Volume:
1.40
時価総額：
$N/A
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-3.16%
1か月 パフォーマンス:
-54.89%
6か月 パフォーマンス:
-75.69%
1年 パフォーマンス:
-92.59%
1日の値動き範囲:
$0.1325
$0.138
1週間の範囲:
$0.1325
$0.138
52週間の値動き範囲:
$0.1325
$0.345
Nkgen Biotech Inc Stock (NKGN) Company Profile
NKGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NKGN
Nkgen Biotech Inc
|
0.138 | 0 | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.11 | 99.26B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
598.71 | 62.06B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.17 | 59.21B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
731.77 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
342.89 | 36.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Nkgen Biotech Inc (NKGN) 最新ニュース
NKGen Biotech CEO to present NK cell therapy data at China forum - Investing.com Australia
NKGen Biotech to Present on the Use of Troculeucel for - GlobeNewswire
Breakthrough NK Cell Therapy for Neurodegenerative Diseases: NKGen Biotech Presents Latest Clinical Data - Stock Titan
LadRx (OTCMKTS:CYTR) & NKGen Biotech (NYSE:NKGN) Head-To-Head Analysis - Defense World
NKGen Biotech announces completion of NKMax acquisition - MSN
NKGen Biotech Acquires Majority Stake in NKMax - TipRanks
NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets - The Manila Times
NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. - GlobeNewswire
$16.9M Strategic Acquisition: NKGen Biotech Gains Full Control of NK Cell Therapy Manufacturing & IP Portfolio - Stock Titan
Cell Dissociation Market Size Projected to Attain USD 1,451.89 Million by 2034 - GlobeNewswire
Alzheimer's Disease Pipeline 2025: Detailed Clinical Trials And FDA-Approved Therapies Review By Delveinsight Neurodon, Sangamo Therapeutics, Nkgen Biotech, Asceneuron, Truebinding, Alector - MenaFN
NKGen Biotech announces new funding to regain compliance with reporting obligations and listing standards - MSN
NKGen Biotech, Inc. (NYSE:NKGN) Short Interest Update - Defense World
NKGen Biotech To Present on Allogeneic Enhanced NK Cells - GlobeNewswire
Breakthrough: NKGen's NK Cell Cancer Therapy Eliminates Need for Harsh Pre-Treatment in Solid Tumors - Stock Titan
Critical Contrast: NKGen Biotech (NYSE:NKGN) & Cortexyme (NASDAQ:CRTX) - Defense World
NKGen Biotech Presents Troculeucel Mechanism of Action with - GlobeNewswire
Revolutionary NK Cell Therapy Transforms Moderate Alzheimer's to Mild Stage in Clinical Trial - Stock Titan
NKGen Biotech to Present at the Alzheimer’s Association International Conference 2025 - GlobeNewswire
Revolutionary NK Cell Therapy Shows Promise in Alzheimer's Disease: Phase 1 Data Reveal Key Insights - Stock Titan
NKGen Biotech Gets FDA Expanded Access - Orange County Business Journal
NKGen Secures FDA Expanded Access For NK Cell Therapy In Neurodegenerative Diseases, Stock Down - Nasdaq
FDA grants expanded access for NKGen’s cell therapy in neurodegenerative diseases By Investing.com - Investing.com South Africa
FDA grants expanded access for NKGen’s cell therapy in neurodegenerative diseases - Investing.com Nigeria
NKGen Receives FDA Expanded Access Protocol Authorization for Landmark Treatment of Several Neurodegenerative Diseases - The Manila Times
NKGen Receives FDA Expanded Access Protocol Authorization - GlobeNewswire
FDA Grants Breakthrough Access: NKGen's NK Cell Therapy Now Available for Multiple Untreatable Brain Diseases - Stock Titan
NKGen Biotech and HekaBio enter strategic partnership to bring novel NK cell therapy to Japan - BioSpectrum Asia
NKGen and HekaBio partner to advance NK cell therapy in Japan - Investing.com India
NKGen Biotech Partners with HekaBio for SNK01 in Japan - TipRanks
NKGen and HekaBio partner to advance NK cell therapy in Japan By Investing.com - Investing.com South Africa
NKGen Biotech and HekaBio Enter Strategic Partnership to Bring Novel NK Cell Therapy to Japan - GlobeNewswire
Vivos Therapeutics shares rise 1.81% premarket after NKGen Biotech's new funding announcement. - AInvest
NKGen Biotech Announces New Funding to Regain Compliance with Reporting Obligations and Listing Standards - GlobeNewswire
NKGen Biotech Secures Funding Amid Compliance Challenges - TipRanks
NKGen Biotech (NYSE:NKGN) versus CEL-SCI (NYSE:CVM) Head-To-Head Comparison - Defense World
Nasdaq Announces Delisting of Multiple Companies Including NKGen Biotech, Aquaron Acquisition Corp, and Others - Quiver Quantitative
Delisting of Securities from The Nasdaq Stock Market - Yahoo Finance
NKGen Biotech (NYSE:NKGN) Stock Price Down 0.2% – What’s Next? - Defense World
NKGen administers first dose of NK cell therapy to Alzheimer’s patient - Investing.com Australia
NKGen administers first dose of NK cell therapy to Alzheimer’s patient By Investing.com - Investing.com South Africa
NKGen Biotech Administers First Dose of Troculeucel to - GlobeNewswire
Breakthrough: New NK Cell Treatment Offers Hope for Alzheimer's Patients Who Failed Standard Therapy - Stock Titan
NKGen activates new sites for Phase I/IIa study of Alzheimer’s cell therapy - Clinical Trials Arena
NKGen Biotech Announces International and U.S. Expansion of - GlobeNewswire
NKGen Biotech Approved as Preferred Bidder for NKMAX - TipRanks
A waste business buy, slashing salaries for all staff: 4 strange strategies biotechs are using to stay alive - Fierce Biotech
NKMAX completes sale to NKGen, eyes delisting prevention and future recoveryCHOSUNBIZ - Chosun Biz
Nkgen biotech sees $2.5 million stock purchase by major shareholder - Investing.com Canada
NKGen Biotech Enters Stock Purchase Agreement - TipRanks
NKGen Biotech Delays Quarterly Report Filing - TipRanks
Nkgen Biotech Inc (NKGN) 財務データ
Nkgen Biotech Inc (NKGN) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.25%
0.14%
大文字化:
|
ボリューム (24 時間):